BioRestorative Therapies, Inc.

Juniper, FL · Medtech · Still private

Peptide-functionalized self-crosslinking polymer hydrogel for mesenchymal stromal cell delivery to treat intervertebral disc degeneration

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · biorestorative.com

Sector: Medtech
Headquarters: Juniper, FL
Latest Form D: $1.4M, Oct 2025
Total capital: $4.8M

Federal grants: $513K; 2 awards · 2021–2022; Rank in peer group#15 of 35
Private capital raised: $4.3M; 5 Form D · last Oct 2025; 13 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 6; 10 pending · first 2019; Rank in peer group#2 of 35

Capital timeline

Latest events

Oct 2025Private capital raisedForm D · SEC · 5th filing$1.4M
Sep 2022Federal grantHealth and Human S · Phase I · Adipokine-enriched brown adipocytes for treating polycystic ovary syndromes$257K
Sep 2021Federal grantHealth and Human S · Phase I · Use of polymer-peptide system to deliver cells for intervertebral disc regeneration$257K
Mar 2014Private capital raisedForm D · SEC · 4th filing$786K
Dec 2013Private capital raisedForm D · SEC · 3rd filing$12K
Apr 2012Private capital raisedForm D · SEC · 2nd filing$2M
Nov 2010Private capital raisedForm D · SEC · 1st filing$135K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 35 peers

Line = median

Medtech · Material

Federal grants#15 · top 43%
Granted patents#2 · top 6%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

A. Jeffrey RadovDirectorNamed in SEC Form D filings
Charles S. RyanDirectorNamed in SEC Form D filings
David A RosaDirectorNamed in SEC Form D filings
Edward L. FieldExecutive OfficerNamed in SEC Form D filings
Francisco Jeffrey SilvaExecutive OfficerNamed in SEC Form D filings
Gloria Jeffrey McConnellPromoterNamed in SEC Form D filings

Show all 19 people

Joel San AntonioDirectorNamed in SEC Form D filings
John M. DesmaraisDirectorNamed in SEC Form D filings
Joseph B. SwiaderDirectorNamed in SEC Form D filings
Lance AlstodtDirector, Executive OfficerNamed in SEC Form D filings
Mandy ClarkExecutive OfficerNamed in SEC Form D filings
Mandy Jeffrey ClydeExecutive OfficerNamed in SEC Form D filings
Mark WeinrebExecutive Officer, DirectorNamed in SEC Form D filings
Nickolay V KukekovDirectorNamed in SEC Form D filings
Patrick F WilliamsDirectorNamed in SEC Form D filings
Paul Jude TonnaDirectorNamed in SEC Form D filings
Robert B. CatellDirectorNamed in SEC Form D filings
Robert KristalExecutive OfficerNamed in SEC Form D filings
Tommy Jeffrey BergerPromoterNamed in SEC Form D filings

What it has protected

USPTO · 6 granted of 16

Apr 3, 2025PendingNon-naturally Occuring Three-dimensional (3D) Brown Adipose-derived Stem Cell Aggregates, And Methods Of Generating And Using The SameUSPTOApplication 18829438
Dec 26, 2023GrantedBrown Fat Cell Compositions And MethodsUSPTOUS 11,851,682
Jun 6, 2023GrantedHuman Brown Adipose Derived Stem Cells And UsesUSPTOUS 11,667,892

Show all 16 patent records

Non-naturally Occuring Three-dimensional (3D) Brown Adipose-derived Stem Cell Aggregates, And Methods Of Generating And Using The SameApr 3, 2025 · Application 18829438Pending
Brown Fat Cell Compositions And MethodsDec 26, 2023 · US 11,851,682Granted
Human Brown Adipose Derived Stem Cells And UsesJun 6, 2023 · US 11,667,892Granted
Brown Fat Cell Compositions And MethodsJul 20, 2021 · US 11,066,646Granted
Non-naturally Occuring Three-dimensional (3D) Brown Adipose-derived Stem Cell Aggregates, And Methods Of Generating And Using The SameMar 18, 2021 · Application 16862226Pending
Human Brown Adipose Derived Stem Cells And UsesMar 9, 2021 · US 10,941,383Granted
Brown Fat Cell Compositions And MethodsMar 24, 2020 · US 10,597,638Granted
Human Brown Adipose Derived Stem Cells and UsesJan 1, 2019 · US 10,167,449Granted
Human Metabolically Active Brown Adipose Derived Stem CellsJul 31, 2014 · Application 14163594Pending
Brown Fat Cell Compositions and MethodsFeb 6, 2014 · Application 13932544Pending
Brown Fat Cell Compositions and MethodsJan 16, 2014 · Application 13932562Pending
Stem Cell Compositions And MethodsApplication PCTUS2012053095Pending
Non-naturally Occuring Three-dimensional (3D) Brown Adipose-derived Stem Cell Aggregates, And Methods Of Generating And Using The SameApplication 62840096Pending
Brown Fat Cell Compositions And MethodsApplication PCTUS2012044651Pending
Human Brown Adipose Derived Stem Cells And UsesApplication PCTUS2014034540Pending
NON-NATURALLY OCCURfNG THREE-DIMENSIONAL (3D) BROWN ADIPOSE-DERIVED STEM CELL AGGREGATES, AND METHODS OF GENERATING AND USING THE SAMEApplication PCTUS2020030520Pending

MIVI Neuroscience, Inc.Similar federal contract value in Medtech · null in contracts
APOLLO ENDOSURGERY US INCSimilar federal contract value in Medtech · null in contracts
Moximed, IncSimilar federal contract value in Medtech · null in contracts
PIROUETTE MEDICALSimilar federal contract value in Medtech · null in contracts
SEALCATH LLCSimilar federal contract value in Medtech · null in contracts
AMG DETECTION, INC.Similar federal contract value in Medtech · null in contracts

Regulatory activity · Medtech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.